- Home
- FRBA vs TKNO Comparison
FRBA vs TKNO Comparison
Compare FRBA & TKNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRBA
- TKNO
- Stock Information
- Founded
- FRBA 2007
- TKNO 1996
- Country
- FRBA United States
- TKNO United States
- Employees
- FRBA N/A
- TKNO N/A
- Industry
- FRBA Major Banks
- TKNO Medicinal Chemicals and Botanical Products
- Sector
- FRBA Finance
- TKNO Health Care
- Exchange
- FRBA Nasdaq
- TKNO Nasdaq
- Market Cap
- FRBA 377.1M
- TKNO 430.2M
- IPO Year
- FRBA N/A
- TKNO 2021
- Fundamental
- Price
- FRBA $14.97
- TKNO $6.09
- Analyst Decision
- FRBA Buy
- TKNO Buy
- Analyst Count
- FRBA 1
- TKNO 2
- Target Price
- FRBA $17.00
- TKNO $5.00
- AVG Volume (30 Days)
- FRBA 49.6K
- TKNO 437.7K
- Earning Date
- FRBA 04-21-2025
- TKNO 03-04-2025
- Dividend Yield
- FRBA 1.60%
- TKNO N/A
- EPS Growth
- FRBA 75.79
- TKNO N/A
- EPS
- FRBA 1.67
- TKNO N/A
- Revenue
- FRBA $128,676,000.00
- TKNO $37,745,000.00
- Revenue This Year
- FRBA $3.24
- TKNO $3.47
- Revenue Next Year
- FRBA $6.26
- TKNO $12.07
- P/E Ratio
- FRBA $8.96
- TKNO N/A
- Revenue Growth
- FRBA 34.24
- TKNO 2.89
- 52 Week Low
- FRBA $11.20
- TKNO $1.16
- 52 Week High
- FRBA $15.87
- TKNO $10.37
- Technical
- Relative Strength Index (RSI)
- FRBA 49.64
- TKNO 34.66
- Support Level
- FRBA $14.55
- TKNO $5.44
- Resistance Level
- FRBA $15.42
- TKNO $6.62
- Average True Range (ATR)
- FRBA 0.39
- TKNO 0.65
- MACD
- FRBA -0.06
- TKNO -0.16
- Stochastic Oscillator
- FRBA 45.16
- TKNO 20.95
About FRBA First Bank
First Bank is a full-service commercial bank, with an emphasis on providing personal and business financial services to individuals and small to mid-sized businesses. The Bank provides its customers with a variety of financial services targeting all segments of the retail and corporate market. Its Business Banking offers commercial deposit accounts, business loans, online banking, and cash management.
About TKNO Alpha Teknova Inc.
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its product offerings include pre-poured media plates for cell growth and cloning, liquid cell culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification. It derives maximum revenue from United States.